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Background: Adenoid cystic cancer arising in the salivary glands has distinctive features such as perineural
invasion, distant metastasis, and a variable prognosis. In salivary gland cancer, c-kit, EGFR, and VEGF are
representative molecular markers that may predict remnant and recurrent tumors. In this study, the expression of
c-kit, EGFR, and VEGF in adenoid cystic cancer was evaluated, and the relationships between the expression of
these markers and the clinical findings were investigated.
Methods: The medical records of 48 patients who were treated for parotid adenoid cystic cancer from January
1990 to January 2006 were reviewed. The tumor location, size, histological subtypes, perineural invasion, the
resected margin status, and lymph node metastasis were assessed. Immunohistochemical staining and
semiquantitative analysis of c-kit, EGFR and VEGF were performed. The relationship between the expression of each
marker and the clinicopathological factors were analyzed.
Results: Positive c-kit immunostaining was present in 45 patients (94%), with weak positivity (+1) in 23, moderate
positivity (+2) in 19 and strong positivity (+3) in three. Positive EGFR immunostaining was observed in 27 (56%),
with weak positivity (+1) in 19 and moderate positivity (+2) in eight with no strong positive staining. Positive VEGF
immunostaining was present in 42 patients (88%) with weak positivity (+1) in 12, moderate positivity (+2) in 17, and
strong positivity (+3) in 13. Only the expression of VEGF was significantly higher in parotid gland tumors than in
any other gland (P = 0.032). Marginal involvement was associated with strong VEGF expression (P = 0.02). No
marker was significantly correlated with recurrence or the survival rate. Lymph node status was related to the
survival rate.
Conclusions: The expression of c-kit, EGRF, and VEGF had no predictive value for recurrence or the prognosis of
adenoid cystic cancer. Only the lymph node status was related to the prognosis.
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Adenoid cystic carcinoma is a relatively rare tumor in
the parotid gland with a 10% incidence, compared with a
30% incidence in the minor salivary glands. Histologi-
cally, this tumor shows higher rates of local growth,
perineural invasion and distant metastasis. Many cases
of delayed recurrence after definite treatment have been
reported, indicating the difficulty of treating and control-
ling this tumor. Factors related to the recurrence and
prognosis of adenoid cystic carcinoma include tumor
stage, histological classification, status of the resected
tumor margin, lymph node metastasis, and perineural
invasion [1-3]. Investigations of the molecular markers
of this tumor and the development of targeted therapy
are currently ongoing. Ki-67, p53, bcl-2, epidermal
growth factor receptor (EGFR), human epidermal
growth receptor-2 (HER2), proliferating cell nuclear
antigen (PCNA), and Runt-related transcription factor-3
(RNUX3) are representative markers of adenoid cystic
carcinoma [4-6]. The inhibition of vascular endothelial
growth factor (VEGF) has also been reported to reduce
local recurrence and distant metastasis [7].
The c-kit protein is a transmembrane receptor with a
tyrosine kinase function. The overexpression of c-kit has
been reported in various malignant tumors [8,9], includ-
ing adenoid cystic carcinoma and some salivary gland
tumors [10,11]. However, there is little information on
the prognostic value of c-kit, and the therapeutic efficacy
of a tyrosine kinase inhibitor (imatinib) is not well estab-
lished [12]. EGFR is a transmembrane receptor found in
epithelial cancers such as breast, lung, bladder, ovary,
prostate, and head and neck cancers [3,13]. The overex-
pression of EGFR in head and neck cancer is associated
with an advanced stage, lymph node metastasis, low sur-
vival rate, and poor response to radiation therapy
[14,15]. Although many studies on the role of EGFR in
salivary gland tumors have been reported, there is some
debate about its prognostic significance [16]. VEGF is a
major vascular formative factor in the process of epithe-
lial carcinogenesis and tumor metastasis. It selectively
functions in the vascular endothelial tissue and is
expressed in various organs such as lung, breast and
gastrointestinal organs [17]. The overexpression of
VEGF is involved in perineural invasion and recurrence,
and it heralds a poor survival rate [18]. In an animal
study, the inhibition of VEGF expression reduced growth
and distant metastasis of adenoid cystic cancer [19].
Clinical trials with a single inhibitor (imatinib for c-kit;
trastuzumab or cetuximab for ErbB1 and ErbB2) have
shown low response rates in salivary gland cancer [20].
Intriguingly, concomitant inhibition of EGF and VEGF
reduced the growth and metastasis of adenoid cystic car-
cinoma in an animal model [19]. EGFR overexpression
and the absence of c-kit expression are negativeprognostic factors in adenoid cystic cancer [21]. Based
on these reports, we hypothesized that the elucidation of
the diverse changes in these proteins would improve
treatment outcomes. In the present study, we evaluated
the relationship between c-kit, EGFR, and VEGF expres-




This retrospective study using medical chart reviews was
performed after approved by the institutional review
board of Asan Medical Center. Written informed con-
sent was obtained from the patients for publication of
this report and any accompanying images. We reviewed
the medical records of 48 patients who were diagnosed
with and treated for salivary adenoid cystic carcinoma
from January 1990 to January 2006 at a single institute.
The presence of lymph node metastasis was preopera-
tively evaluated by neck ultrasonography (US), computed
tomography (CT), and magnetic resonance imaging
(MRI). Tumor locations were divided into the subman-
dibular, parotid, and minor salivary glands. Distant me-
tastasis was identified with Tc99m bone scanning and
F18-flurodeoxyglucose positron emission tomography
(F18-FDG PET). We investigated tumor size, the histo-
logical pattern, the presence of perineural invasion, inva-
sion of surgical margins, and lymph node metastasis
according to the pathology reports. The histological pat-
terns were classified as tubular, cribriform, and solid
types on the basis of the WHO classification (2005).
Marginal involvement included microscopic and macro-
scopic invasion of the margin of the specimen. When
lymph node metastasis was confirmed on preoperative
fine needle aspiration cytology with or without US,
therapeutic neck dissection from level I to V was per-
formed. Selective neck dissection, including levels I to
III, was performed in cases of clinical T3, T4 or suspi-
cious findings on radiology. Lymph node metastasis was
defined when confirmed histologically after surgery. A
close resection margin (<1 cm from the tumor), an un-
clear margin, a perineural invasion, and an advanced
stage (III, IV) were indications for adjuvant radiation
therapy. We also checked for local recurrence, distant
metastasis, and survival after treatment [22,23]. The ob-
servation period was defined from the end point of treat-
ment to the most recent follow-up date.
Tissue microarray blocks
Two tissue microarray blocks were made from the for-
malin-fixed, paraffin-embedded tissue of the 48 patients
with adenoid cystic carcinoma. Each slide was reviewed
under a microscope, and representative areas were
selected for immunohistochemistry. These were marked
Table 1 Characteristics of patients and tumors
Characteristics Category Number of patients (%)
Sex Male 19 (40)
Female 29 (60)
Site Submandibular 12 (25)
Parotid 18 (38)
Minor 18 (38)




Perineural invasion Negative 26 (54)
Positive 22 (46)
Resection margin Negative 21 (44)
Positive 27 (56)
Lymph node involvement Negative 42 (88)
Positive 6 (13)
Treatment Surgery only 10 (21)
Surgery + RT 32 (67)
Surgery + CCRT 6 (13)
Mean (± SD)
Age (years) 49.7 (± 14.2)
Tumor size (cm) 2.5 (± 1.2)
PET (SUV) 3.0 (± 1.2)
CCRT, concurrent chemoradiation therapy; PET, positron emission tomography;
RT, radiation therapy; SUV, standard uptake value.
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their corresponding areas on each block were punched
using a tissue cylinder with a 0.6 mm diameter. These
cores were transferred to the recipient blocks using a
tissue-arraying instrument (Beecher Instruments, Silver
Spring, MD, USA). Considering the heterogeneity of the
tumor, the samples were arrayed in duplicate to avoid
tissue loss.
Immunohistochemistry
Immunohistochemical staining for c-kit, EGFR, and
VEGF was performed using a Benchmark automatic
immunostaining device (Ventana Medical Systems,
Tucson, AZ, USA). Tissue sections (4 μm thick) were
deparaffinized in 10% xylene, dehydrated in 100%, 95%,
and 75% ethanol solutions, and washed with distilled
water. For antigen retrieval, the sections were immersed
in 10 mM citrate buffer (pH 6.0) and microwaved for 10
min. Endogenous peroxidases activities and nonspecific
antigens were eliminated with 3% hydrogen peroxide in
methanol and AB blocker (Roche, Basel, Switzerland).
The sections were incubated with primary antibodies
against c-kit (CD117, 1:400 dilution; DAKO, Glostrup,
Denmark), EGFR (1:500 dilution; DAKO), and VEGF
(1:100 dilution; Zymed, South San Francisco, CA, USA).
Immunodetection was performed with biotinylated anti-
mouse immunoglobulin followed by peroxidase-labeled
streptavidin, using a labeled streptavidin-biotin kit
(DAKO). As a chromogen, 3,3’-diaminobenzidine was
used, and the sections were counterstained with Harris
hematoxylin. The intensity of the immunohistochemical
staining of c-kit (membranous/cytoplasmic), EGFR
(membranous), and VEGF (cytoplasmic) was semiquan-
titatively scored as 0 (reactivity in <5% of the tumor
cells), 1+ (reactivity 5% - 1/3 of the tumor cells), 2+
(reactivity in 1/3 to 2/3 of the tumor cells), or 3+ (re-
activity >2/3 of the tumor cells). Cases with scores of 2+
and 3+ were regarded as positive.
Statistical analysis
SPSS software (version 14.0; SPSS Inc., Chicago, IL,
USA) was used for the statistical analysis. To identify
relationships between clinical factors and immunostain-
ing of markers, Fisher’s exact test was used for categor-
ical data and the Mann–Whitney U test was used for
continuous variables. Univariate and multivariate ana-
lyses using Cox’s proportional hazard model were per-
formed with a backward, stepwise elimination approach.
At each step, the least significant factor with P >0.10
was eliminated, and each remaining factor in the model
was reassessed. The limit for including factors was set at
20%. To simplify binary logistic regression analyses, we
divided the data into two groups based on immunoreac-




Forty-eight patients (19 males and 29 females) with ade-
noid cystic cancer in the salivary gland were enrolled. The
average patient age was 49.7 years (± 21.9). The numbers
of tumors that involved the submandibular gland, parotid
gland, or minor salivary gland were 12 (25%), 18 (38%),
and 18 (38%), respectively. The average tumor size was 2.6
cm (± 2.2). Twenty-seven cases were classified into three
groups (tubular, two cases (4%); cribriform, 18 cases (38%);
solid, seven cases (15%)) according to the histology, and 21
cases (44%) had no records or had unclear tumor types.
Perineural invasion and cervical lymph node metastasis
were identified in 22 (56%) and six (13%) cases, respect-
ively. Twelve patients underwent PET, and the average
standard uptake value in the primary lesion was 3.0 (± 2.1).
Ten patients (21%) underwent only surgical management,
while 32 (67%) received adjuvant radiation therapy after
surgery. Concurrent chemoradiation therapy following sur-
gery was administered in six cases (14%) (Table 1).
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Forty-five cases (94%) showed c-kit immunoreactivity,
with 23 weakly positive, 19 moderately positive, and
three strongly positive cases. For EGFR, 27 cases (56%)
were positive, comprising 19 weakly positive and eight
moderately positive cases; no strongly positive cases
were observed. Forty-two cases (88%) showed positive
immunoreactivity for VEGF: 12 were weakly positive, 17
were moderately positive, and 13 were strongly positive
(Figure 1). The patients were divided into two groups, a
negative or weakly positive group and a more-than-
moderately positive group, according to the staining in-
tensity for c-kit and VEGF. For EGFR, patients were
divided into negative and positive groups. There was no
significant correlation between the staining intensity for
each marker (c-kit and EGFR, P = 0.422; EGFR and
VEGF, P = 0.499; VEGF and c-kit, P = 0.454). VEGF
showed stronger expression in the parotid gland
(P = 0.032) than in the other sites, and marginal invasion
was frequent in cases with high VEGF expression (P = 0.02).
The other makers showed no notable trends (Table 2).
Recurrence after treatment
The mean follow-up period was 70.9 months (range, 4.0
to 159.1 months). There were 19 patients (39.6%) withFigure 1 Immunohistochemical staining of adenoid cystic carcinomas
moderately (2+, B), and strongly positive (3+, C) cases; EGFR (epidermal gro
(E) cases; VEGF (vascular endothelial growth factor) expression of weakly (F
(membranous/cytoplasmic), EGFR (membranous), and VEGF (cytoplasmic) w
in 5% -1/3 of tumor cells; 2+, reactivity in 1/3 to 2/3 of tumor cells; 3+, rearecurrence, and the average time until detection of re-
currence was 24.9 months (range, 2.0 to 97.6 months).
Four cases showed local recurrence, 10 showed distant
metastasis (lung, nine cases; multiple, one case), and five
showed both local and distant metastasis. Lymph node
metastasis was closely related to recurrence after the ini-
tial treatment (P <0.001). However, recurrence was not
associated with the staining intensity of c-kit (P = 0.987),
EGFR (P = 0.747), or VEGF (P = 0.927) (Table 3).
Survival rate
Eleven patients died of the disease, and the mean sur-
vival period was 38.0 months (range, 4.4 to 144.2
months). The five-year survival rate was 88.2%, and the
complete remission rate was 72.9%. No marker staining
intensity was associated with a difference in survival rate
based on the Kaplan-Meier survival curve, whereas
lymph node metastasis was significantly related to
survival rate (Figure 2). Using Cox’s proportional hazard
model, we analyzed the factors that might have
influenced the survival rate, and only lymph node
metastasis showed a close relationship to the survival
rate (P = 0.049). The expression of c-kit (P = 0.864),
EGFR (P = 0.716), and VEGF (P = 0.198) did not show a
close relationship with the survival rate (Table 4).of the salivary gland. C-kit (CD 117) expression of weakly (1+, A),
wth factor receptor) expression of weakly (D) and moderately positive
), moderately (G), and strongly positive (H) cases. Expressions of c-kit
ere scored as follows: 0, reactivity in <5% of tumor cells; 1+, reactivity
ctivity >2/3 of tumor cells.
Table 2 Correlation between expression of tumor markers and clinical factors
c-kit EGFR VEGF
Clinical factor 0, 1+ 2+, 3+ P 0 1+, 2+ P 0, 1+ 2+, 3+ P
Sex Male 12 7 0.312 9 10 0.683 6 13 0.493
Female 14 5 12 17 12 17
Site Submandibular gland 5 7 0.149 6 6 0.53 1 11 0.032
Parotid gland 8 10 6 12 7 11
Minor salivary gland 13 5 9 9 10 8
Histology Tubular 1 1 0.961 0 2 0.633 0 2 0.8
Cribriform 9 9 7 11 7 11
Solid 4 3 4 3 2 5
Indeterminate 12 9 10 11 9 12
Perineural invasion Negative 15 11 0.594 12 14 0.715 8 18 0.295
Positive 11 11 9 13 10 12
Resection margin Negative 13 8 0.343 7 14 0.199 11 10 0.02
Positive 13 14 14 13 7 20
Lymph node involvement Negative 24 18 0.392 17 4 0.383 16 26 1
Positive 2 4 25 2 2 4
EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
Table 3 Effect of tumor markers and clinical factors on tumor recurrence
Marker/factor HR 95% CI P
c-kit 0, 1+ 1 0.402 - 2.45 0.987
2+, 3+ 0.993
EGFR 0 0.862 0.349 - 2.129 0.747
1+, 2+ 1
VEGF 0, 1+ 0.958 0.386 - 2.377 0.927
2+, 3+ 1
Sex Male 1 0.195 - 1.212 0.122
Female 0.486
Site Submandibular gland 1
Parotid gland 0.392 0.18 - 1.45 0.153
Minor salivary gland 0.81 0.266 - 2.468 0.71
Histology Tubular 1
Cribriform 0.513 0.061 - 4.283 0.538
Solid 3.727 0.423 - 32.813 0.236
Indeterminate 0.446 0.053 - 3.781 0.459
Perineural invasion Negative 1 0.384 - 2.405 0.932
Positive 0.961
Resection margin Negative 1 0.224 - 1.406 0.217
Positive 0.561
Lymph node involvement Negative 1 2.178 - 19.982 <0.001
Positive 6.597
Treatment Surgery only 1
Surgery + RT 0.89 0.192 - 4.122 0.881
Surgery + CCRT 4.002 0.793 - 20.197 0.093
Age (years) 0.949 0.902 - 0.998 0.071
Tumor size (cm) 0.864 0.566 - 1.318 0.498
CCRT, concurrent chemoradiation therapy; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; RT, radiation therapy; VEGF, vascular
endothelial growth factor.
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Figure 2 Overall survival curves of the patients according to (A) c-kit, (B) epidermal growth factor receptor (EGFR), (C) vascular
endothelial growth factor (VEGF) expression, and (D) lymph node metastasis. Survival curves were calculated using the Kaplan-Meier
method and analyzed by the log-rank test.
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The low response rate of adenoid cystic cancer to tyro-
sine kinase inhibitors and EGFR inhibitors indicates that
no single molecule is dominant in tumor invasion and
spread of this cancer [19-21,24]. The class III receptor
tyrosine kinase and c-kit is important for normal
hematopoiesis, melanin production and reproductive cell
production. Imatinib mesylate (Gleevec™), a tyrosine kin-
ase inhibitor, is very effective in treating chronic myeloid
leukemia and show good efficacy for the treatment of
advanced gastrointestinal tumors with positive c-kit ex-
pression [24]. The expression of c-kit in salivary adenoid
cystic cancer has been variably reported as 78% to 100%.
The high c-kit expression in adenoid cystic cancer
suggests that this cancer may respond to treatment with
imatinib mesylate, although studies with imatinib have
not shown consistent results [12,25]. The relationship
between c-kit expression and prognosis has been contro-
versial, although the expression of c-kit was stronger in
the tubular or cribriform type than in the solid type[21,26]. The discrepancy might have been caused by
differences in staining techniques and the lack of a
standard method for evaluating staining intensity. In the
present investigation, 94% of the tumors expressed c-kit,
but no significant relationship with other clinical vari-
ables or prognosis was identified.
EGF is found in the primary duct and terminal buds,
and its distribution and density decrease with aging [27].
EGFR is present in salivary gland tumors, with expression
reported in 0% to 85% of adenoid cystic cancers [27]. In
the present study, 56% of the tumors were positive for
EGFR. The overexpression of EGFR is reportedly related
to a poor prognosis in salivary gland cancer [21], which is
different from our results. VEGF promotes vascular prolif-
eration in tumors from peripheral tissue and enhances
vessel permeability with a selective effect on vascular
endothelial cells. VEGF expression is found in various
tumors, such as those of esophageal cancer, small cell lung
cancer, thyroid cancer, breast cancer, and cervical cancer
[28], as well as head and neck cancer. VEGF expression is
Table 4 Effect of tumor markers and clinical factors on survival
Marker/factor HR 95% CI P
c-kit 0, 1+ 1 0.297 - 4.251 0.864
2+, 3+ 1.124
EGFR 0 1 0.206 - 2.957 0.716
1+, 2+ 0.781
VEGF 0, 1+ 1 0.624 - 11.392 0.198
2+, 3+ 2.623
Sex Male 1 0.01 - 0.639 0.17
Female 0.8
Site Submandibular gland 1
Parotid gland 0 0.995
Minor salivary gland 0.33 0.07 - 1.563 0.162
Perineural invasion Negative 1 0.491- ~ 7.02 0.362
Positive 1.856
Resection margin Negative 1 0.173 - 2.505 0.54
Positive 0.659
Lymph node involvement Negative 1 0.791 - 14.06 0.049
Positive 4.362
Treatment Surgery only 1
Surgery + RT 0.224 0.033 - 1.508 0.124
Surgery + CCRT 0.831 0.113 - 6.127 0.856
Age (year) <45 1
≥45 1.078 1.016 ~ 1.143 0.103
Tumor size (cm) ≤2 1
>2 0.838 0.452 ~ 1.554 0.575
CCRT, concurrent chemoradiation therapy; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; RT, radiation therapy; VEGF, vascular
endothelial growth factor.
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cancer stage, perineural invasion, recurrence, and low sur-
vival [18,28]. Higher VEGF expression was found in solid
tumors compared with tubular or cribriform types, and
the survival rate decreased with higher VEGF expression
[29]. In the present study, there was no relationship be-
tween high VEGF expression and lymph node metastasis,
recurrence, or survival, contrary to our expectations. This
was possibly, attributable to the subjective assessment of
the differences in immunostaining and the semiquantita-
tive analysis. A few investigations on treatments targeting
VEGF in salivary gland cancer have shown partial remis-
sion, suggesting the targeting of VEGF for the manage-
ment of adenoid cystic cancer [30]. Negative results
regarding the prognostic usefulness of molecular markers
in the present study might have been due to the threshold
criteria used for positive EGFR, c-kit, and VEGF on
immunoreactivity [21]. The availability of normal tissue as
a negative control would have helped in scoring positive
immunochemical staining.
Histological differentiation in adenoid cystic cancer is
variable and reflects its malignant potential [31]. Indeter-
minate cases comprised 44% of all cases in the presentstudy, and most of these were mixed type with no
predominant type. This result was attributable to a lack
of detailed pathologic reports on subtypes, which is a
limitation of the present retrospective study. In addition,
tumor size and involved sites were not recorded defini-
tively enough to be analyzed. Lymph node metastasis
alone was significantly associated with the prognosis.
Previous studies have reported that perineural invasion
had strong relationships to distant metastasis and the
survival rate [32,33]. These relationships were not sig-
nificant in the present investigation because of the small
number of cases. In earlier studies, cervical lymph node
metastasis was present in 20% of adenoid cystic cancers
and was related to a high recurrence rate and low
survival rate [34,35]. A similar pattern of metastasis was
observed in the present study. Distant metastasis was
observed in 10 cases, with the lung being the most
frequently involved single site (n = 9). Multiple sites
(lung, bone, and brain) were involved in one case.
Recurrence of adenoid cystic cancer has been found
usually within 56 months. Death occurred within three
years after the detection of distant metastasis in 54%,
whereas survival in excess of 10 years was recorded in
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recurrence is characteristic of adenoid cystic cancer, the
analysis of recurrence during a short follow-up period is
another limitation of the present study.
Lymph node metastasis is a key step in the develop-
ment of metastasis and is a determining factor of prog-
nosis. Traditionally, it has been thought that tumors
spread to lymph nodes by direct extension in an orderly,
defined manner based on mechanical considerations and
transverse lymphatics [38]. However, lymph node metas-
tasis cannot explain local recurrence, distant metastasis,
or poor treatment outcomes. Based on clinical and
laboratory research, Fisher has proposed that biological,
rather than anatomical, factors may be responsible for
the appearance of metastasis in certain nodes and the
lack of metastasis in others, suggesting that cancer is not
a local disease, but a systemic disease [39]. Oligometas-
tasis implies a critical interaction between systemically
disseminated cancer cells and the host; this concept
leads to the notion that confined distant metastasis
could be completely cured by local therapy in some
cases [40]. Based on these ideas, we believe that lymph
node metastasis is both a key step and coincident find-
ing. Thus, an analysis of markers specific for lymph node
metastasis may be useful for stratifying prognosis.
Anticancer radiation therapy for head and neck cancer
can reduce local recurrence, but not distant metastasis
[23,41]. The molecular markers used in the present
study are related to the prognosis of other head and
neck malignancies, including salivary gland tumors.
Although we did not identify the prognostic significance
of these molecular markers, immunohistochemical stain-
ing revealed high expression levels of c-kit, EGFR and
VEGF in the present study. These findings indicate a
need for further research on these markers in adenoid
cystic cancer.
Conclusions
Lymph node metastasis was the only factor that was
related to recurrence and survival rate following treatment
of salivary adenoid cystic cancer. Despite the high expres-
sion levels of c-kit, EGFR, and VEGF, these markers were
not significantly correlated with recurrence and the
prognosis of adenoid cystic cancer. However, the expres-
sion levels of c-kit, EGFR, and VEGF exhibited variable
changes, suggesting that interrelationships among these
proteins may provide approaches for molecularly targeted
therapy for salivary adenoid cystic cancer.
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